How has been the historical performance of Vanta Bioscience?

Answer:The historical performance of Vanta Bioscience shows a fluctuating trend in net sales and profitability over the years, with significant losses in recent periods. Breakdown: Vanta Bioscience's net sales for March 2024 were reported at 9.72 Cr, an increase from 6.28 Cr in March 2023, but a slight decrease from 9.69 Cr in March 2022. The total operating income followed a similar pattern, with 9.72 Cr in March 2024 compared to 6.28 Cr in March 2023. The company experienced a total expenditure of 8.41 Cr in March 2024, slightly down from 8.67 Cr in March 2023. Operating profit, excluding other income, was 1.31 Cr in March 2024, a recovery from a loss of 2.39 Cr in March 2023. However, the company reported a profit before tax of -2.54 Cr in March 2024, an improvement from -6.30 Cr in March 2023. The net profit also showed a loss of -2.32 Cr in March 2024, compared to -6.48 Cr in March 2023. The total assets of the company increased to 85.40 Cr in March 2024 from 84.71 Cr in March 2023, while total liabilities rose to 85.40 Cr in March 2024 from 84.71 Cr in March 2023. Cash flow from operating activities was 2.00 Cr in March 2024, a recovery from 0.00 Cr in March 2023, while cash flow from investing activities was -3.00 Cr in March 2024, indicating ongoing investments despite the losses. Overall, Vanta Bioscience has shown some signs of recovery in sales and operating profit, but continues to face challenges with profitability and cash flow.